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Abstract— The following review article in brief describes the definition, pathophysiology, management, preoperative assessment and 
perioperative anesthesia management in a case of pheochromocytoma. 
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I. INTRODUCTION  
heochromocytomas are defined as catecholamine 
secreting tumors that arise from chromaffin cells of 
adrenal medulla in 90% of cases or sympathetic 
ganglia referred to as adrenal and extra adrenal 
pheochromocytoma or paraganglioma respectively. 
Paragangliomas can arise in the paravertebral sympathetic 
chain anywhere along the chain. 95% are localised to 
abdomen, and rest arise from thorax, urinary bladder, or neck, 
these can also be seen to be present in right atrium, broad 
ligament of ovary, or organ of Zuckerkandl. 
Pheochromocytomas can secrete both epinephrine and 
norepinephrine, however percentage of secreted 
norepinephrine is more than that secreted by normal glands. 
Pheochromocytomas are suspected when patients present with 
classical symptoms and suggest a family history and in some 
cases by an incidental finding of adrenal mass. Approximately 
3% to 10% of adrenal ―incidentalomas‖ prove to be 
pheochromocytomas.  
History of Pheochromocytoma-(table I) 
 
TABLE I. Important discoveries related to Pheochromocytoma. 
Year Scientist Comments 
1886 Felix Frankel 
First made the description of a patient with 
pheochromocytoma 
1912 
Ludwig Pick (a 
pathologist) 
Term pheochromocytoma was first coined by 
him. 
1926 
Cesar Roux and 
Charles Mayo 
They were the first surgeons to successfully 
remove pheochromocytoma 
Adrenergic Receptors  
1) Alpha adrenergic receptors 
a. α1- vasoconstriction, intestinal relaxation, uterine 
contraction, and pupillary dilatation. 
b. α2- decreases presynaptic NE,  platelet aggregation, 
vasoconstriction, decrease Insulin Release 
2) Beta Adrenergic receptors 
a. β1- Increase Heart rate/ contractility,  Increase renin. 
b. β2- Vasodilatation, Bronchodilatation, Increase 
glycogenolysis and Increase gluconeogenesis 
c. β3-Increase lipolysis, Increase brown fat 
thermogenesis. 
Effect of various agonist drugs on adrengeric receptors 
varies in several parameters. (Table II) 
TABLE II. Effect of adrenergic agonist drugs. 
DRUGS HR MAP CO PVR 
BRONCHO- 
-DILATION 
RBF 
Epinepherine ↑↑ ↑ ↑↑ ↑/↓ ↑↑ ↓↓ 
Ephedrine ↑↑ ↑↑ ↑↑ ↑ ↑↑ ↓↓ 
Nor epinephrine ↓ ↑↑↑ ↑/↓ ↑↑ 0 ↓↓ 
Dopamine ↑↑ ↑ ↑↑↑ ↑ 0 ↑↑↑ 
Dopexamine ↑↑↑↑ ↑/↓ ↑↑ ↑ 0 ↑ 
Isoproterenol ↑↑↑ ↓ ↑↑↑ ↓↓ ↑↑↑ ↑/↓ 
Dobutamine ↑ ↑ ↑↑↑ ↓ 0 ↑ 
 
Pheochromocytoma presents with classic triad of symptoms: 
1. Headache which occur episodically 
2. Sweating 
3. Tachycardia 
TABLE III. Classical triad of pheochromocytoma. 
 
 
 Paroxysmal Hypertension is a classical sign of 
pheochromocytoma, however is non-specific for the 
disease. It is present in half of the patients, whereas most 
of the remaining patients have essential hypertension 
 5-10% of the patients have normal Blood pressure 
 Headache is present in approximately 90% of symptomatic 
patients, however is variable in severity 
 Sweating is present in 60-70% of patients 
P 
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TABLE IV. Rule of Ten in Pheochromocytoma. 
 
 
Effect of disease on different systems: 
1. Cardio vascular system:  
 Depends on relative proportion of Epinephrine, 
Norepinephrine or Dopamine release. Majority secrets-
Norepinephrine. Nausea and Vomiting are features of 
Dopamine secreting tumour. 
 Norepinephrine - Hypertension with bradycardia. 
 Epinehprine - systolic hypertension, diastolic 
hypotension, tachycardia, palpitations, dyspnea, 
weakness and panic attacks. Sometimes MI / Failure, 
Dilated Cardiomyopathy (because of excess 
catecholamines), polycythemia and orthostatic 
hypotension. 
 
2. Central Nervous system : 
 Anxiety, Psychosis, Tremors, Hypertensive 
encephalopathy, Blurred vision and Psychiatric 
disorders 
 
3. Metabolic disturbances : 
 Hyperglycemia, Hypermetabolism and weight loss, 
Polyuria and Polydipsia. 
 
4. Suspicion of pheochromocytoma:  
 Hyper adrenergic spells (nonexertional palpitations, 
diaphoresis, headache, tremor, pallor), Hypertension 
that is difficult to control. 
 Familial syndrome that includes catecholamine 
secreting tumors (e.g., MEN 2, neurofibromatosis type 
1, von Hippel–Lindau disease) (These individuals often 
have bilateral disease.) 
 Family history of pheochromocytoma with incidentally 
discovered adrenal mass.  
 Unusual BP response during anesthesia, surgery, or 
angiography.  
 Hypertension at a young age (e.g., <20 years old). 
 Idiopathic dilated cardiomyopathy. A history of gastric 
stromal tumor or pulmonary chondromas (Carney 
triad) 
Complications: 
Complications of pheochromocytoma are because of 
unopposed action of high blood pressure on critical organs 
such as heart, brain and kidneys, and include Cerebrovascular 
accidents, acute kidney failure, acute respiratory distress, 
myocardial infarction, sudden heart attack and damage to 
nerves of eye.  
Diagnosis is made as a combination of Clinical signs and 
symptoms, Biochemical tests and Radiological tests. (Table V) 
 
Clinical diagnosis By classical Signs and symptoms 
Biochemical Tests- no single test is 
perfect 
1. Free catecholamine levels in 
24 hour urine 
2. Plasma free metanephrine 
3. Urinary metanephrine 
4. Urinary VMA 
 
5. Clonidine suppression test 
 
 
 
 
 
 
6. Provocative tests 
 
 
 
Familial 
 
 
Urinary VMA is the oldest and 
inexpensive test 
Clonidine is a centrally acting α-2 
agonist, which inhibits central 
neurogenic mediated 
catecholamine release but not 
catecholamine released 
autonomously by 
pheochromocytoma. 
Provocative tests (histamine, 
tyramine, Glucagon, 
metoclopramide and naloxone) 
used to stimulate catecholamine 
secretion from 
pheochromocytomas. 
ECG: 
Left ventricular hypertrophy and 
nonspecific T-wave changes are 
two of the more common ECG 
findings. Evidence of acute 
myocardial infarction or 
tachyarrhythmia.  
Chest X ray 
The chest radiograph may reveal 
cardiomegaly  
Blood Count- CBC 
Often shows an elevated 
hematocrit consistent with a 
reduced intravascular volume and 
hemoconcentration. 
Radiological tests: 
a) MRI/CT –  
b) MIBG (Metaiodo benzyl 
guanidine)-  
c) Positron emission scans. 
d) Selective adrenal venous 
catheterisation and sampling. 
e) USG and MRI useful especially in 
pregnant patients. 
f) Arteriography must be performed 
with extreme care in these patients 
because a hypertensive crisis can 
be precipitated. 
It is used in the non-invasive 
localization of these tumors. 
taken up by tumor , helpful in 
localizing recurrent tumor and 
extra- adrenal masses 
 
Pre Operative Management 
The reduction in perioperative mortality rates from a high 
of 45% to between 0% and 3% with the excision of 
pheochromocytoma is attributed to the introduction of α-
antagonists for preoperative therapy. However many drugs can 
be employed for adequate BP optimisation before surgery. 
1. Perioperative blood pressure fluctuations, myocardial 
infarction, congestive heart failure, cardiac dysrhythmias, 
and cerebral haemorrhage all appear to be reduced in 
frequency when the patient has been treated before surgery 
with alpha blockers and the intravascular fluid 
compartment has been re-expanded.  
International Research Journal of Pharmacy and Medical Sciences 
 ISSN (Online): 2581-3277 
 
 
31 
 
Bhavna Gupta, Lalit Gupta, and Kamna Kakkar, ―Anesthesia Considerations for Pheochromocytoma,‖ International Research Journal of 
Pharmacy and Medical Sciences, Volume 1, Issue 1, pp. 29-33, 2018. 
2. Extended treatment with α-antagonists is also effective in 
treating the clinical manifestations of catecholamine 
myocarditis. 
3. All patients with pheochromocytoma must be managed 
with preoperative α-adrenergic blockade at least 7 to 10 
days before the surgical procedure, with the goal of 
normalizing BP and volume status. 
4. Phenoxybenzamine is the preferred drug for preoperative 
preparation to control arterial BP and arrhythmias.  
 Phenoxybenzamine is an irreversible non-specific long 
acting alpha adrenergic blocking drug 
 Initial dosage is 10 mg OD or BD, and is increased by 
10-20 mg every 48-72 hours to control blood pressure 
 Most patients are controlled with 20-100 mg of 
phenoxybenzamine 
 Blood pressure is measures two times in a  day with 
patient lying, sitting and standing 
 Target blood pressure is less than 120/80 mmHg and 
SBP <90mmHg while standing 
 Patients should be told about common side effects such 
as fatigability, orthostatic hypotension and nasal 
congestion 
5. Selective α1-adrenergic blocking agents (e.g., prazosin, 
terazosin, doxazosin) are preferable to phenoxybenzamine 
when long-term pharmacologic treatment is indicated (e.g., 
metastatic pheochromocytoma) because of the favourable 
side effect profiles of these drugs. The disadvantage of 
using these agents preoperatively is their incomplete 
degree of α-adrenergic blockade, thus resulting in more 
episodes of intraoperative hypertension. Preoperative 
preparation with phenoxybenzamine is associated with 
more post-resection hypotension than is preparation with 
selective α1-adrenergic blocking agents.  
6. After adequate α-adrenergic blockade is achieved, β-
adrenergic blockade may be started cautiously with short-
acting drugs.  
 After 24 to 48 hours, if the patient tolerates β-
adrenergic blockade, a long-acting preparation (e.g., 
metoprolol, atenolol) can be substituted.  
 The dose is then adjusted to control tachycardia with an 
HR goal of 60 to 80 beats/minute.  
 β-Adrenergic blockade should never be initiated before 
α-adrenergic blockade because blockade of 
vasodilatory peripheral β-adrenergic receptors with 
unopposed α-Adrenergic receptor stimulation can lead 
to a further elevation in BP.  
 Clonidine, dexmedetomidine, and magnesium, have 
also been used to achieve suitable degrees of α-
adrenergic blockade preoperatively.  
 Perioperative α-adrenergic blockade is most commonly 
used, another option involves the administration of a 
calcium channel blocker. Nicardipine is the most 
commonly used calcium channel blocker for 
pheochromocytoma management. The main role for 
calcium channel blockers is likely to supplement α- and 
β-adrenergic blockade when BP control is inadequate 
or in patients with intolerable side effects 
 Nicardipine inhibit catecholamine release by blocking 
calcium entry.  
 They are effective in controlling both hypertension 
and tachycardia, when used as a single agent or 
with α-blockers.  
 The starting dose of the sustained release preparation 
is 30 mg orally twice a day. 
7. Others: 
 Patients with acute hypertensive crises require 
hospitalization and treatment with intravenous sodium 
nitroprusside, phentolamine, or nicardipine.  
 Magnesium therapy has shown efficacy for the resection of 
pheochromocytoma or paraganglioma during pregnancy.  
 Unrecognized pheochromocytoma during pregnancy may 
be life threatening to the mother and fetus. Although the 
safety of adrenergic-blocking agents during pregnancy has 
not been established, these agents probably improve fetal 
survival in pregnant patients with pheochromocytoma.  
The trend is to perform surgery during the first trimester or 
at the time of cesarean delivery. There is no reason to 
terminate an early pregnancy, but the patient should be 
aware of the risk of spontaneous abortion resulting from 
abdominal surgery to remove the tumor. 
 
TABLE VI. Anti-hypertensive drugs. 
Drug Action Pre Operative BP Control Pressor Crisis Comments 
Phenoxybenzamine 
Non-Selective alpha 1 
antagonist 
20-160 mg/day per oral - Long half-life may accumulate 
Doxazosine Selective alpha1 antagonist 1-8 mg/day po - First dose effect, syncope. 
Propanolol 
Non selective beta 
antagonist 
40-480 mg/day in divided 
dosage 
1-2 mg iv bolus 
Should never be given alone without 
alpha blockade 
Atenolol Selective beta 1 antagonist 50-100 mg/day  Long acting, unchanged by renal 
Esmolol   
250-500 µgm/min followed by 
infusion 25-250 µgm/min 
Half life 9 minutes 
Labetolol Alpha and beta antagonist 200-800 mg/day 10 mg iv bolus Weak alpha blockade 
SNP Direct vasodilator  
0.5-1.5 µgm /kg/min initially, 
max 8 µgm /kg/min 
Powerful vasodilator, short acting 
MgSO4 
Direct vasodilator and 
membrane stabilizer 
 
2-4g iv bolus, followed by 1-2 
g/h 
Potentiates NM blockade 
Nicardapine Calcium channel antagonist  
1-2 µgm /kg/min, max 7.5 µgm 
/kg/min 
 
Alpha-
methyltyrosine 
Inhibits biosynthesis of 
catecholamine’s 
1-4 g/day  
Suitable for patients not amenable to 
surgery, nephrotoxic. 
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Rozen Criteria 
The following criteria are reasonable for assessing the 
adequacy of treatment: 
1. No in-hospital arterial blood pressure reading higher than 
165/90 mm Hg should be evident for 48 hours 
preoperatively. Measure arterial blood pressure (at 
specified interval like evry 5 min) for 1 hour in a stressful 
environment (Postanesthesia care unit). If no blood 
pressure reading is higher than 165/90 mm Hg, this 
criterion is considered satisfied. 
2. Orthostatic hypotension is acceptable as long as arterial 
blood pressure when the patient is standing is not less than 
80/45 mm Hg. 
3. The ECG should be free of ST-T changes that are not 
permanent. 
4. No more than one premature ventricular contraction (PVC) 
should occur every 5 minutes. 
 
Differential diagnosis 
1. Anxiety disorders, including Benzodiazepine withdrawal 
syndrome 
2.  Paragangliomas 
3. Von Hippel–Lindau Disease 
4. Essential hypertension 
5. Hyperthyroidism 
6. Insulinoma 
7. Mercury poisoning 
8. Paroxysmal supraventricular tachycardia 
9. Renovascular hypertension 
10. Carcinoid 
 
Surgical approaches 
The principles of adrenalectomy for pheochromocytoma are: 
1. Complete tumor resection. 
2. Minimal tumor manipulation in avoidance of tumor seeding 
and hypertensive crisis. 
3. Control of vascular supply. 
4. Adequate exposure to avoid other organ injury. 
5. In MEN associated adrenal medullary disease, surgical 
options include bilateral adrenalectomy or cortical-sparing 
subtotal adrenalectomy for adrenal medullary hyperplasia. 
 
Operative approaches for adrenalectomy include:  
1. Open anterior transabdominal approach. 
2. Open thoracoabdominal approach. 
3. Open posterior or lateral retroperitoneal approach. 
4. Lateral transabdominal laparoscopic approach. 
5. Posterior retroperitoneal laparoscopic approach. 
Perioperative Anesthesia Management 
Symptomatic patients continue to receive medical therapy 
until tachycardia, cardiac dysrhythmias, and paroxysmal 
elevations in blood pressure are well controlled. If it is not 
possible to initiate α-blocking therapy before surgery, or if the 
patient has received less than 48 hours of intensive treatment, 
it may be necessary to infuse nitroprusside during the 
induction of anesthesia. A low-dose infusion is often initiated 
in anticipation of the marked blood pressure elevations that 
can occur with laryngoscopy and surgical stimulation 
Improvements in imaging now allow most patients with 
solitary tumors without evidence of metastases or local 
invasion to undergo a laparoscopic retroperitoneal approach.  
If the surgeon needs to assess for bilateral disease or the 
dissection is too difficult, then the procedure can be converted 
to an open one. During laparoscopic surgery, creation of the 
pneumoperitoneum may cause release of catecholamines and 
large changes in hemodynamics that can be controlled with a 
vasodilator.  
Intraoperative management: Understand pharmacology and 
physiology: 
Drugs that should be avoided include: Drugs that inhibit 
catecholamine uptake, drugs releasing histamine and that 
cause indirect increase in catecholamines. Drugs include 
droperidal, Morphine, Atracurium, Pancuronium, Ketamine, 
Ephedrine, Halothane, Cocaine, Metoclopramide, and Scoline. 
1. Intraoperative Goals of management include: 
 Avoid manoeuvres/drugs causing catecholamine 
release 
 Maintain stability by short acting drugs 
 Maintain normovolumia 
2. The time periods of instability in which we anticipate 
surges of blood pressure include: 
 Induction and intubation 
 Incision 
 Pneumoperitoneum 
 Exploration and manipulation 
 Ligation of venous drainage 
 
3. Monitoring during anesthesia management of a case of 
pheochromocytoma include: 
 Electrocardiogram 
 Pulse oximeter 
 End tidal carbon dioxide 
 Temperature probe 
 Invasive lines (CVP/ Arterial) 
 Cardiac Output monitoring ± 
 Urinary catheter. 
 
Anesthesia technique: 
General Anaesthesia +/- Epidural (Low thoracic) 
1. Avoid stress, Anxiety, Pain, Hypoxia, Hypercarbia and 
Drugs - mentioned earlier.  
2. Blood glucose should be monitored closely 
3. Maintain Normothermia.  
4. Although there is no clear advantage to one anesthetic 
technique over another, drugs that are known to liberate 
histamine are avoided. Virtually all anesthetic drugs and 
techniques (including isoflurane, sevoflurane, sufentanil, 
remifentanil, and fentanyl) have been used with 
success.Because of the potential for ventricular irritability, 
halothane is not administered. 
5. A potent sedative-hypnotic, in combination with an opioid 
analgesic, is used for induction. It is extremely important 
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to achieve an adequate depth of anaesthesia before 
proceeding with laryngoscopy to minimize the sympathetic 
nervous system response to this maneuver. Painful or 
stressful events such as intubation often cause an 
exaggerated stress response in less than perfectly 
anesthetized patients who have pheochromocytoma. This 
response is caused by release of catecholamines from 
nerve endings that are ―loaded‖ by the reuptake process.  
6. Slight stresses may result in catecholamine levels of 200 to 
2000 pg/mL in normal patients. For a patient with 
pheochromocytoma, even simple stress can lead to blood 
catecholamine levels of 2000 to 20,000 pg/mL.  Infarction 
of a tumor, with release of products onto peritoneal 
surfaces, or surgical pressure causing release of products, 
can result in blood levels of 200,000 to 1,000,000 
pg/mL—a situation that should be anticipated and avoided 
(ask for a temporary stay of surgery, if at all possible, 
while the rate of nitroprusside infusion is increased).  
7. Maintenance is provided with an opioid analgesic 
(fentanyl, sufentanil, Remifentanil) and a potent inhalation 
agent (Isoflurane, sevoflurane).  
8. Acute hypertensive crises are treated with intravenous 
infusions of nitroprusside or phentolamine.  
 Phentolamine is a short-acting α-adrenergic antagonist 
that may be given as an intravenous bolus (2 to 5 mg) 
or by continuous infusion.  
 Tachydysrhythmia can be controlled with intravenous 
boluses of propranolol (1-mg increments) or by a 
continuous infusion of the ultrashort-acting selective 
β1- adrenergic antagonist esmolol.  
 The disadvantage of long-acting beta-blockers may be 
persistence of bradycardia and hypotension after the 
tumor is removed. Even esmolol may be problematic 
because there are cases of cardiac arrest after clamping 
of the venous drainage in patients on large doses of 
esmolol.  
 Almost every vasodilator has been tried and 
recommended as an adjuvant to control hypertension. 
 Magnesium sulfate given as an infusion with 
intermittent boluses has successfully controlled blood 
pressure. 
  Nicardipine, nitroglycerin, diltiazem, fenoldopam, and 
prostaglandin E1 have all been used. The reduction in 
blood pressure that may occur after ligation of the 
tumor's venous supply can be dangerously abrupt and 
should be anticipated through close communication 
with the surgical team.  
 Restitution of any intravascular fluid deficit is the 
initial therapy in this situation. After replenishment of 
the intravascular volume, if the patient remains 
hypotensive, phenylephrine is administered. After 
surgery, catecholamine levels return to normal over 
several days.  
 Approximately 75% of patients become normotensive 
within 10 days. 
Problems in Post Operative Period 
A) Hypotension 
•  Drop in catecholamines 
•  Residual alpha blockade. 
•  Down regulation. 
•  Suppression of normal adrenal 
•  Hypovolemia from blood/ fluid loss. 
•  Myocardial dysfunction. 
• TREATMENT: fluids, vasopressors, vasopressin, 
glucocorticoids (B/L adrenalectomy) 
B) Very somnolent: 
•  Due to sudden removal of activating catecholamines. 
•  Rule out hypoglycemia. 
C) Hypoglycemia: 
• Decrease epinephrine. 
• Increase plasma insulin 
• No gluconeogenesis and glycogenolysis. 
• Give glucose containing fluids and monitor blood 
glucose. 
D) Persistent hypertension 
•  Residual/Renal ischemia/Essential HTN 
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